Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says - 2The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- 3Grasping the Elements of Medical caretaker Pay rates: Factors That Shape Your Pay
- 4Creative Style: 10 Architects Reclassifying the Business
- 5German Winemakers Rewrite The Rules Of Riesling In A Warming World
- Living Abroad: Social Inundation and Self-improvement
- Figure out how to Guarantee Your Dental Embeds Endure forever
- Well known Travel Booking Locales: What's Your Pick?
- Bolsonaro discharged from hospital and placed under house arrest
- Which Kind of Pet Makes the Incomparable Buddy?
- New heart disease calculator predicts 30-year risk for young adults
- Manual for Individual accounting Rudiments for Fledglings
- Vote In favor of Feasible Way You Prescribe to Shop for Garments
- Space station changes command, setting stage for Crew 11 departure
